Immupharma PLC Holding(s) in Company (5484N)
October 26 2016 - 10:42AM
UK Regulatory
TIDMIMM
RNS Number : 5484N
Immupharma PLC
26 October 2016
RNS : FOR IMMEDIATE RELEASE 26 OCTOBER 2016
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, announces that it has received a TR-1 by
Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma
is now confirmed at a total of 10,521,555 Ordinary Shares which
equates to a current position in the Company of 8.4%.
Full disclosure of the TR1 is shown below:
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Panmure, Gordon & Co., (NOMAD +44 (0) 20
& Broker) 7886 2500
Freddy Crossley, Duncan Monteith,
Corporate Finance
Charles Leigh-Pemberton, Corporate
Broking
Northland Capital Partners Limited
(Joint Broker)
Patrick Claridge, David Hignell,
Corporate Finance
Rob Rees, John Howes, Corporate +44 (0)20 3861
Broking 6631
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Immupharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
----------------------------------------------------------- ---------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
----------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights x
------------------------------------------------------------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------------------------------------
Other (please The placement by ImmuPharma PLC of x
specify): 2,857,143 new ordinary shares
---------------------------------------------------------- ------------------------------------
3. Full name of person(s) Lanstead Capital LP
subject to the
notification obligation:
(iii)
----------------------------------------------------------- ---------------------------------------
4. Full name of shareholder(s)
(if different from 3.):(iv)
----------------------------------------------------------- ---------------------------------------
5. Date of the transaction 21 October 2016
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ---------------------------------------
6. Date on which issuer 25 October 2016
notified:
----------------------------------------------------------- ---------------------------------------
7. Threshold(s) that is/are
crossed or
reached: (vi, vii) 14%, 13%, 12%, 11%, 10%, 9%
----------------------------------------------------------- ---------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- -------------------------------- ---------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
------------- --------------- --------------- ------------- --------------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ----------- ----------- ------------- ------------- ------------ ------------ -----------
GB0033711010 17,893,456 17,893,456 10,521,555 10,521,555 8.44%
--------------- --------------- ------------- ------------- ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ------------- ------------------------------ ----------------------------- ---------------------
N/A
----------------- ------------- ------------------------------ ----------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- ------------- ------------- --------------- ----------------------------- -----------------------
N/A Nominal Delta
--------------- ------------- ------------- --------------- ----------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------------------------------- -------------------------------------------------------------------
10,521,555 8.44%
------------------------------------------------- -------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
----------------------------------------------------------------------------------------
N/A
Proxy Voting:
----------------------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------- -------------------------
11. Number of voting rights proxy
holder will cease to hold:
------------------------------------------------------------- -------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
------------------------------------------------------------- -------------------------
13. Additional information:
------------------------------------------------------------- -------------------------
14. Contact name: Lisa De Vargas, Lanstead
Partners Limited
------------------------------------------------------------- -------------------------
15. Contact telephone number: +1 (801) 895-3700
------------------------------------------------------------- -------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLZQLFLQBFXFBQ
(END) Dow Jones Newswires
October 26, 2016 10:42 ET (14:42 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
